Therapeutics: Multiple kinase targets; an undisclosed target

Cancer

INDICATION: Cancer; breast cancer; lung cancer

Mouse studies suggest the mitochondrial inhibitor ME-344 and/or the multikinase inhibitor Vargatef nintedanib could help treat kinase inhibitor-resistant cancers. In a mouse model of Stivarga regorafenib-resistant metastatic breast

Read the full 332 word article

User Sign In

Article Purchase

This article may not be distributed to non-subscribers

PURCHASE THIS ARTICLE FOR LIMITED ONE-TIME DISTRIBUTION AND WEBSITE POSTING $995.00 USD

PURCHASE